Home>Topics>Stocks>Cadence Pharmaceuticals

Cadence Pharmaceuticals CADX

  1. All
  2. Commentary
  3. Headlines
    1. Mallinckrodt Reports Strong 4Q Results, but Shares Remain Overvalued

      Commentary

      Thu, 7 Aug 2014

      uncertainty surrounding Questcor. Revenue in the quarter was up 15% due to the inclusion of the recently acquired Cadence Pharmaceuticals business and its sole product, Ofirmev. Excluding the acquisition, sales grew 5%. Ofirmev results were

    2. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

      Headlines

      Thu, 26 Jun 2014

      BBB from BBB+. Mallinckrodt MNK "> MNK will double its debt leverage to nearly 5 times in order to acquire Cadence Pharmaceuticals . While the deal gives Mallinckrodt a new platform to build out a hospital-focused pharmaceutical business

    3. Mallinckrodt Continues Its Acquisition Binge With Questcor Merger

      Commentary

      Mon, 7 Apr 2014

      billion merger with Questcor. The deal comes less than a month after Mallinckrodt closed its acquisition of Cadence Pharmaceuticals . The transaction will be funded approximately 35% with debt financing, and 65% with shares of Mallinckrodt

    4. Mallinckrodt's Acquisition of Cadence Pharmaceuticals Looks Like a Stretch

      Commentary

      Tue, 11 Feb 2014

      Mallinckrodt announced today that is acquiring Cadence Pharmaceuticals for $1.3 billion. The deal gives Mallinckrodt a new platform to build out a hospital-focused pharmaceutical business, but

    5. Cadence Pharma falls to life-low on disappointing results

      Headlines

      Fri, 4 May 2012

      (Reuters) - Cadence Pharmaceuticals Inc's shares fell to their life-low after the biopharmaceutical company reported a larger-than-expected first-quarter loss on costs related to the recall of its...

    6. Dropping Coverage of Cadence Pharmaceuticals

      Commentary

      Mon, 29 Aug 2011

      We are no longer providing equity research on Cadence Pharmaceuticals CADX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    7. Cadence's Fourth-Quarter Costs Beat Our Expectations

      Commentary

      Fri, 4 Mar 2011

      Cadence Pharmaceuticals CADX reported fourth-quarter results with costs coming in below our expectations. However, this did not have a material impact on

    8. Approval for Cadence Pharma's Lead Drug

      Commentary

      Thu, 4 Nov 2010

      Cadence Pharmaceuticals CADX received Food and Drug Administration approval for lead drug candidate Ofirmev, an intravenous acetaminophen. At first glance

    9. Impending FDA Decision for Cadence Drug

      Commentary

      Mon, 4 Oct 2010

      We're maintaining our fair value on Cadence Pharmaceuticals CADX as we await a Food and Drug Administration decision on its lead drug candidate Ofirmev (formerly known as Acetavance). The agency has set an action date of November 4.

    10. Cadence Signs Option for Incline

      Commentary

      Fri, 25 Jun 2010

      Cadence Pharmaceuticals CADX announced recently that it signed an option to acquire private firm Incline Therapeutics, which develops a device, Ionsys, that

    « Prev123Next »
    Content Partners